These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37978019)

  • 21. Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant.
    Li M; Peng H; Duan G; Wang J; Yu Z; Zhang Z; Wu L; Du M; Zhou S
    Front Public Health; 2022; 10():1014470. PubMed ID: 36268004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of outpatient SARS-CoV-2 reinfection and recurrence rates and associated factors among COVID-19 hospitalized patients over one-year old: a multicenter retrospective cohort study.
    Mokhayeri Y; Taherpour N; Shahbazi F; Ghorbani SS; Fallah S; Etemad K; Izadi N; Mehri A; Farhadi-Babadi K; Rahimi E; Feyzi R; Seifi A; Hashemi Nazari SS
    BMC Infect Dis; 2024 Sep; 24(1):999. PubMed ID: 39294562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
    Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
    Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis.
    Flacco ME; Acuti Martellucci C; Baccolini V; De Vito C; Renzi E; Villari P; Manzoli L
    Eur J Clin Invest; 2022 Oct; 52(10):e13845. PubMed ID: 35904405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
    Lin DY; Xu Y; Gu Y; Zeng D; Wheeler B; Young H; Moore Z; Sunny SK
    Lancet Infect Dis; 2023 Nov; 23(11):1257-1265. PubMed ID: 37336222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
    Wei J; Stoesser N; Matthews PC; Khera T; Gethings O; Diamond I; Studley R; Taylor N; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
    Nat Commun; 2024 Feb; 15(1):1008. PubMed ID: 38307854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants.
    Monge S; Rojas-Benedicto A; Olmedo C; Martín-Merino E; Mazagatos C; Limia A; Sierra MJ; Larrauri A; Hernán MA;
    Clin Infect Dis; 2023 Feb; 76(3):e367-e374. PubMed ID: 35687580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
    Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
    Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection from infection and reinfection due to the Omicron BA.1 variant in care homes.
    Choudhry S; Rowland TAJ; McClelland K; Renz E; Iyanger N; Chow JY; Aiano F; Ladhani SN; Jeffery-Smith A; Andrews NJ; Zambon M
    Front Immunol; 2023; 14():1186134. PubMed ID: 37936695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients.
    Slezak J; Bruxvoort K; Fischer H; Broder B; Ackerson B; Tartof S
    Clin Microbiol Infect; 2021 Dec; 27(12):1860.e7-1860.e10. PubMed ID: 34419576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of SARS-CoV-2 reinfection in a paediatric cohort in Kuwait.
    Alhaddad F; Abdulkareem A; Alsharrah D; Alkandari A; Bin-Hasan S; Al-Ahmad M; Al Hashemi H; Alghounaim M
    BMJ Open; 2022 Jun; 12(6):e056371. PubMed ID: 35768102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease severity during SARS-COV-2 reinfection: a nationwide study.
    Mensah AA; Lacy J; Stowe J; Seghezzo G; Sachdeva R; Simmons R; Bukasa A; O'Boyle S; Andrews N; Ramsay M; Campbell H; Brown K
    J Infect; 2022 Apr; 84(4):542-550. PubMed ID: 35085659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiological assessment of SARS-CoV-2 reinfection.
    Almadhi M; Alsayyad AS; Conroy R; Atkin S; Awadhi AA; Al-Tawfiq JA; AlQahtani M
    Int J Infect Dis; 2022 Oct; 123():9-16. PubMed ID: 35931371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
    Cegolon L; Negro C; Mastrangelo G; Filon FL;
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
    [No Abstract]   [Full Text] [Related]  

  • 39. Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.
    Rothberg MB; Kim P; Shrestha NK; Kojima L; Tereshchenko LG
    Clin Infect Dis; 2023 Feb; 76(3):e142-e147. PubMed ID: 35867678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
    Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
    Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.